From: Cyclin H expression is increased in GIST with very-highrisk of malignancy
Initial symptoms (multiple mentions possible) | n | % of 90 | |
---|---|---|---|
No clinical symptoms | 25 | 28% | |
Pain | 33 | 37% | |
GI bleeding | 25 | 28% | |
Anemia | 6 | 7% | |
Localization of primary tumour | n | % of 95 | |
Stomach | 58 | 61% | |
Small bowel | 29 | 31% | |
Jejunum | 9 | 9% | |
Ileum | 17 | 18% | |
Duodenum | 3 | 3% | |
Colon | 1 | 1% | |
Esophagus | 2 | 2% | |
Others (EGIST, etc.) | 5 | 5% | |
Second neoplasias | n | % of 95 | |
Total | 30 | 32% | |
n | % of 30 | ||
Colorectal cancer | 5 | 17% | |
Prostate cancer | 4 | 13% | |
Breast cancer | 3 | 10% | |
Gastric cancer | 3 | 10% | |
Myometrial or cervical cancer | 2 | 7% | |
Renal or urothelian cancer | 2 | 7% | |
Pancreatic cancer | 1 | 3% | |
Others | 10 | 33% | |
Histomorphology | n | % of 92 | |
Spindle cell GIST | 80 | 87% | |
Epithelioid/Mixed pattern | 12 | 13% | |
Mixed pattern | 11 | 12% | |
Epithelioid | 1 | 1% | |
Risk of Malignancy (Fletcher et al.) | n (sto/smbo/ot) | n | % of 93 |
High risk | 21/13/5 | 39 | 42% |
Intermediate risk | 13/5/1 | 19 | 20% |
Low risk | 14/7/0 | 21 | 23% |
Very low risk | 8/4/2 | 14 | 15% |